Evaluation of Intermittent Triple Therapies in Real Life

NCT06578702 | Recruiting

• 1 other identifier: 9238
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al. Currently this strategy is proposed by some teams in France, but is not recommended internationally. The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.

Conditions

HIV Infections

Keywords

HIV Infections; Intermittent Triple Therapy

Outcome Measures

Primary Outcomes (1)

• Evaluation of HIV viral load

  48 weeks after reduction of the HIV viral load

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult subject (≥ 18 years old) living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg and having benefited from intermittent triple therapy

You may qualify if:

• Adult subject (≥ 18 years old)
• Living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg
• Having benefited from intermittent triple therapy between 01/01/2017 and 31/01/2024

You may not qualify if:

• Subject (and/or their legal representative if applicable) having expressed their opposition to the reuse of their data for scientific research purposes.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service Le Trait d'Union - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Central Study Contacts

Axel URSENBACH, MD

CONTACT

33 3 69 55 13 52; axel.ursenbach@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2024
• First Posted: August 29, 2024
• Study Start: February 21, 2024
• Primary Completion: February 1, 2025
• Study Completion: February 21, 2025
• Last Updated: August 29, 2024

Record last verified: 2024-08

Locations

FR (1)